CDC (Centers for Disease Control and Prevention) forewarns on HIV kit shortage
This article was originally published in Clinica
Executive Summary
The Centers for Disease Control and Prevention (CDC) says there is a risk of a possible shortage of supplemental test kits used for confirmatory testing of HIV antibodies in blood samples. Calypte Biomedical announced in April that it might stop manufacturing the Cambridge Biotech HIV-1 Western blot kit. The kit is one of two such FDA licensed kits on the market. The other is the Genetic Systems Western blot kit made by BioRad. A third product, made by OraSure Technologies, is approved for supplemental testing of oral fluid samples found reactive for antibodies to HIV-1.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.